- Home
- CNEY vs BCAB Comparison
CNEY vs BCAB Comparison
Compare CNEY & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNEY | BCAB |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 6.4M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CNEY | BCAB |
|---|---|---|
| Price | $0.57 | $3.34 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.6M | 44.0K |
| Earning Date | 02-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.12 |
| 52 Week High | $2.95 | $6.52 |
Technical Indicators
Market Signals| Indicator | CNEY | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 42.65 |
| Support Level | $0.58 | $3.31 |
| Resistance Level | $1.10 | $4.24 |
| Average True Range (ATR) | 0.14 | 0.30 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 21.66 | 21.45 |
Price Performance
Historical ComparisonAbout CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.